<div id="readability-page-1"><div>** Shares of Ascentage Pharma Group International rise 6.8% to HK$65, their highest level since November 27** Stock on track for the biggest one-day pct gain since August 5 ** Ascentage receives clearance from US FDA and European Medicines Agency for a phrase III (POLARIS-1) study of its blood cancer drug olverembatinib** The POLARIS-1 trial is a global, multicenter, randomized controlled, open-label study designed to evaluate the efficacy and safety of olverembatinib in combination with chemotherapy in newly diagnosed patients with certain types of leukemia ** Stock up 37% YTD; Hang Seng Biotech Index (.HSBIO) up 78.8%</div></div>

AAPGV

AAPG

Ascentage Pharma's stock rose 6.8% to HK$65 following FDA and EMA clearance for a Phase III study of olverembatinib for blood cancer treatment. The POLARIS-1 trial will assess the drug's efficacy and safety in combination with chemotherapy for leukemia. The stock is up 37% YTD, while the Hang Seng Biotech Index is up 78.8%.

Ascentage rises on progress of olverembatinib for blood cancer treatment